Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers
about
A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone lossCrucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic painIn vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain modelsTime-Dependent Protection of CB2 Receptor Agonist in StrokeExpression of functional cannabinoid CB2 receptor in VTA dopamine neurons in ratsContributions of academic laboratories to the discovery and development of chemical biology toolsThe endocannabinoid system in anxiety, fear memory and habituation.Selective effects of D- and L-govadine in preclinical tests of positive, negative, and cognitive symptoms of schizophreniaAntinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: lack of dependence upon opioid receptor activation.Differential activation of intracellular versus plasmalemmal CB2 cannabinoid receptors.CB2: a cannabinoid receptor with an identity crisisThe plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice.WAY-318068: a novel, potent and selective noradrenaline re-uptake inhibitor with activity in rodent models of pain and depression.Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic painCB2 Cannabinoid receptors as a therapeutic target-what does the future hold?Brain cannabinoid CB₂ receptors modulate cocaine's actions in miceThe promise and dilemma of cannabinoid therapy: lessons from animal studies of bone disease.The role of cannabinoids in regulation of nausea and vomiting, and visceral pain.Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in ratsSpecies differences in cannabinoid receptor 2 and receptor responses to cocaine self-administration in mice and ratsPrimary Macrophage Chemotaxis Induced by Cannabinoid Receptor 2 Agonists Occurs Independently of the CB2 Receptor.Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands.Therapeutic modulation of cannabinoid lipid signaling: metabolic profiling of a novel antinociceptive cannabinoid-2 receptor agonistThe novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist LEI-101 prevents cisplatin-induced nephrotoxicity.Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences.Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain.Emerging strategies for exploiting cannabinoid receptor agonists as medicines.Selective cannabinoid receptor 2 modulators: a patent review 2009--present.The added value of proteomics for toxicological studies.The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets.MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models.Central and peripheral sites of action for CB₂ receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in ratsConstitutive activity of cannabinoid-2 (CB2) receptors plays an essential role in the protean agonism of (+)AM1241 and L768242.Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors.Review: The Role of Cannabinoids on Esophageal Function-What We Know Thus Far.Dronabinol increases pain threshold in patients with functional chest pain: a pilot double-blind placebo-controlled trial.Use of the harmonic mean to the determination of dissociation constants of stereoisomeric mixtures of biologically active compounds.Identification of two new-type synthetic cannabinoids, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide (APICA) and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA), and detection of five synthetic cannabinoids, AM-1220, AM-2233, AM-1241,
P2860
Q24615787-07145EF0-4FB7-4882-8672-9843D2437668Q24634161-ED7A0B37-F334-48BC-B6E2-D5FD3FB8AD1AQ24643672-48242EC2-1D97-42B9-8F7A-792899DA6793Q27302924-E990A5BA-777D-4AF1-A3CF-01E7A0EBCADCQ28272826-512B39D4-AB23-40DD-A0EC-9E0451FA9FCFQ28389188-217C6257-102F-404B-9322-C4C6C92ED336Q30471032-B07BC9D4-15D6-4934-BA14-7F6C466A7EA8Q30578267-BDF9D080-381B-4170-AC5D-BD407B8625BAQ33749455-D544342D-EC86-401E-AC1D-9EE1648756E3Q34089051-07FC4AD3-0991-4032-A3E6-BFB8BAA9F3CAQ34098185-E4BF8D9D-361E-4142-B8C1-7997134F5A73Q34098266-FC5020A0-5A01-40FC-A0C6-2ABBB50BB28BQ34112969-54750713-31D4-4651-ADA1-78A14023966DQ34118976-BB43AB4F-4B65-4FE6-9A57-066CEA6C9108Q34186015-6226104E-34BF-413A-9346-3151F59A810FQ34203193-A29E888A-9D1A-4726-9C4B-D58B19B02C8FQ34393890-0697AF35-0D54-4EE5-BA30-E4CE6F9B58D6Q34464535-73BC82B6-7403-4987-BF25-23EE030488F4Q34802605-2A2B09E0-239E-49CA-A2BD-959DB2E14F67Q35089428-0998A0DE-38B5-46C4-BA7D-E234281A6378Q35672413-38A6B7AF-8772-4966-935B-EDFCA89913E2Q35688511-88EC7355-63B3-4439-9E1C-DA524052538BQ36385052-9C119AB0-CAF5-4BEC-925D-B2142A78220FQ36506869-FFF684DB-2327-4700-8EAA-794B57911637Q36887138-63E9B5FF-B047-49F1-B288-2BB88A23595BQ36997712-ED69D203-AF2B-42AB-8500-6FD075BA5B17Q37230665-F1AA52AA-F38A-45AD-BC94-7729F3B527C0Q38005740-3BA43128-B9B9-454C-BAF6-AF4507E26EF3Q38211782-501348A5-642F-4F5C-BDA6-299A8A784B94Q38600704-F541927A-081A-4B15-8985-7DCD20886D8AQ39021630-73CB1401-3903-4696-972A-0FF667F3EBB9Q41139755-78DCFE07-B260-419E-993E-D3F78DEDC194Q42585836-9E84E3D2-CAC0-4EAF-80B3-CE24D7BD9580Q42951315-F02AB7A6-A5E4-42E5-A0A0-76C5D54FB844Q43120926-1F2C0CDA-44DA-4B50-9DB0-4E5BBAC326EAQ47446813-1D11C964-6298-49AF-A246-F3B6F1FD7EF7Q48065211-C82129F8-7AC1-48F4-A93D-87BD346FEE89Q51112892-3F1F6484-1DE7-4CF9-9438-BB1A4B2F83CAQ56460366-D6EAF3C4-2DA8-4441-99F4-AA6D1B26797C
P2860
Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers
description
2007 nî lūn-bûn
@nan
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Species-specific in vitro phar ...... 1 and its resolved enantiomers
@ast
Species-specific in vitro phar ...... 1 and its resolved enantiomers
@en
Species-specific in vitro phar ...... 1 and its resolved enantiomers
@nl
type
label
Species-specific in vitro phar ...... 1 and its resolved enantiomers
@ast
Species-specific in vitro phar ...... 1 and its resolved enantiomers
@en
Species-specific in vitro phar ...... 1 and its resolved enantiomers
@nl
prefLabel
Species-specific in vitro phar ...... 1 and its resolved enantiomers
@ast
Species-specific in vitro phar ...... 1 and its resolved enantiomers
@en
Species-specific in vitro phar ...... 1 and its resolved enantiomers
@nl
P2093
P2860
P921
P356
P1476
Species-specific in vitro phar ...... 1 and its resolved enantiomers
@en
P2093
A J Uveges
B W Strassle
G T Whiteside
J D Kennedy
J E Harrison
M J Piesla
P2860
P304
P356
10.1038/SJ.BJP.0707303
P407
P577
2007-08-01T00:00:00Z